Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Circadian rhythm refers to the internal biological clock in which various processes in the body, including immune cell activity, are controlled by the time of day. Exactly how this works is not fully understood, and the researchers want to see if circadian rhythm control of the immune system can influence response to immunotherapy based on whether it is given in the morning (before 11:00 am) or afternoon (12:00pm). The time of day that immunotherapy is given (morning versus afternoon) may impact the effectiveness in treating patients with advanced or metastatic solid tumors.
Sponsor: OHSU Knight Cancer Institute
You may qualify if…
- ✓ Must provide written informed consent before any study-specific procedures or interventions are performed
- ✓ Aged ≥ 18 years
- ✓ Histologically confirmed advanced/metastatic solid tumor as follows:
- ✓ Non small cell lung cancer (NSCLC) (driver-negative, immune checkpoint inhibitor \[ICI\]-eligible)
- ✓ Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) (platinum-eligible),
- ✓ Renal cell carcinoma (RCC)
- ✓ Biliary-tract cancer (BTC)
- ✓ Hepatocellular carcinoma (HCC)
You may not qualify if…
- ✕ Prior ICI-based regimen for treatment of cancer
- ✕ Current or prior use of immunosuppressive medication within 28 days before planned standard-of-care immunotherapy infusion, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses not exceeding 10 mg/day of prednisone (or equivalent corticosteroid)
- ✕ Uncontrolled autoimmune disease requiring immunosuppression
- ✕ Active, uncontrolled central nervous system (CNS) metastases
Where it's recruiting
Portland
Source: ClinicalTrials.gov · NCT07405086 · last updated 2026-06-12